This study looks at GCase enzyme activity and GBA gene-related biomarkers in patients with dementia with Lewy bodies, aiming to identify a subgroup of patients who might be eligible for a future therapeutic trial. It enrolled patients aged 50 and over with this diagnosis, along with healthy individuals for comparison. This is a study without a phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria for patients : * Male or female aged ≥ 50 years old * Presence of an accompanying person * Dementia with lewy bodies according to the revised criteria of Mc Keith 2017 Inclusion Criteria for controls: * Male or female aged ≥ 50 years old * Absence of cognitive impairment and clinical element for a neurodegenerative disease Exclusion Criteria for patients: * Other neurodegenerative disease * Gaucher disease Exclusion Criteria for controls: * Neurodegenerative disease * Cognitive impairment of all causes